Creso Pharma achieves second consecutive quarter of record revenue growth

• Total revenue generated during the quarter ended 30 June 2021 (Q2 CY2021) of A$1,715,933 – a 24% increase on the previous quarter (Q1 CY2021: A$1,385,000)

• Q2 CY2021 revenue marks a 451% increase on the previous corresponding period (Q2 CY2020: A$311,353)

• Strong sales growth witnessed through Swiss operations and wholly-owned Canadian subsidiary Mernova Medical Inc.

• Multiple purchase orders (“PO”) from various provinces highlight increased demand for Mernova’s products in Canada and scalable recurring revenue model

• Creso has a positive outlook on sales growth, with potential Red Light Holland (“RLH”) merger providing multiple new near term market entries and scale up opportunities

• Sales growth represents the second quarter of consecutive record revenue for the Creso Pharma Group

• Ongoing growth demonstrates Company’s strategy to create consistent revenue generation across all business divisions